Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

Table 1 Demographic and baseline patients’ characteristics

Demographic and baseline patient characteristics (n = 8 patients, 100%)
Age (years old)
< 65	3 (37.5%)
≥ 65	5 (62.5%)
Race
Asian	2 (25%)
White	3 (37.5%)
African	3 (37.5%)
American
Ethnicity
Hispanic	2 (25%)
Non-Hispanic	6 (75%)
Weight (kg)
Minimum	56.7
Median	71.95
Maximum	111.3
Height (cm)
Minimum	161
Median	170
Maximum	179
BMI (kg/m2)
Minimum	19.2
Median	26.68
Maximum	39.9

Table 2 Fold of changes in hypoxia inducible factor-1αlpha mRNA by qPCR

Number	Patient ID	Specimen 1 at tip site(fold changed)	Specimen 2 at root site(fold changed)
11	2886230004 (super-responder) 1	0.91	0.191

Specimen 1 is the tip of the biopsy, and specimen 2 is the other end of biopsy. A difference in the number of cycles was assumed to be a 2-fold difference.

¹The results of the patient who had a robust clinical response in partial response.

Table 3 The difference in K^trans for the tumor and the liver between pre and post-treatment

Pre-treatment	Post-treatment
Tumor
Ktrans pre-treatment: 849 × 10-3/min	Ktrans post-treatment: 122 × 10-3/min
Liver (left lobe)
Ktrans pre-treatment: 245 × 10-3/min	Ktrans post-treatment: 255 × 10-3/min

K^trans is a measurement in dynamic contrast-enhanced magnetic resonance imaging to determine tissue perfusion and permeability. After 1 cycle of treatment, K^trans in the patient with PR demonstrated decrease from baseline (Table 3) in the tumor, while K^trans in the liver remained stable during the 2 time period.